Cargando…
Challenging the rationale of routine vasopressor therapy for management of hypotension
There is persuasive evidence, including the present report by Dubin and colleagues, of a dissociation between increases in arterial pressure produced by vasopressor agents and improvement in microvascular perfusion and delivery of vital substrates. Especially in settings of septic shock, the current...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750173/ https://www.ncbi.nlm.nih.gov/pubmed/19691820 http://dx.doi.org/10.1186/cc7976 |
_version_ | 1782172219792687104 |
---|---|
author | Weil, Max Harry Tang, Wanchun |
author_facet | Weil, Max Harry Tang, Wanchun |
author_sort | Weil, Max Harry |
collection | PubMed |
description | There is persuasive evidence, including the present report by Dubin and colleagues, of a dissociation between increases in arterial pressure produced by vasopressor agents and improvement in microvascular perfusion and delivery of vital substrates. Especially in settings of septic shock, the current routine administration of adrenergic vasopressor therapy therefore may fail to reverse the primary defect. |
format | Text |
id | pubmed-2750173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27501732010-08-14 Challenging the rationale of routine vasopressor therapy for management of hypotension Weil, Max Harry Tang, Wanchun Crit Care Commentary There is persuasive evidence, including the present report by Dubin and colleagues, of a dissociation between increases in arterial pressure produced by vasopressor agents and improvement in microvascular perfusion and delivery of vital substrates. Especially in settings of septic shock, the current routine administration of adrenergic vasopressor therapy therefore may fail to reverse the primary defect. BioMed Central 2009 2009-08-14 /pmc/articles/PMC2750173/ /pubmed/19691820 http://dx.doi.org/10.1186/cc7976 Text en Copyright ©2009 BioMed Central Ltd |
spellingShingle | Commentary Weil, Max Harry Tang, Wanchun Challenging the rationale of routine vasopressor therapy for management of hypotension |
title | Challenging the rationale of routine vasopressor therapy for management of hypotension |
title_full | Challenging the rationale of routine vasopressor therapy for management of hypotension |
title_fullStr | Challenging the rationale of routine vasopressor therapy for management of hypotension |
title_full_unstemmed | Challenging the rationale of routine vasopressor therapy for management of hypotension |
title_short | Challenging the rationale of routine vasopressor therapy for management of hypotension |
title_sort | challenging the rationale of routine vasopressor therapy for management of hypotension |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750173/ https://www.ncbi.nlm.nih.gov/pubmed/19691820 http://dx.doi.org/10.1186/cc7976 |
work_keys_str_mv | AT weilmaxharry challengingtherationaleofroutinevasopressortherapyformanagementofhypotension AT tangwanchun challengingtherationaleofroutinevasopressortherapyformanagementofhypotension |